Published on Tuesday, December 4, 2018
The Alpha-1 Foundation was informed by CSL Behring that Zemaira, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1), returned to normal distribution on Monday, December 3rd, 2018. This is good news for patients who rely on this product, especially as we head into the cold and flu season.
The Foundation bases its knowledge of this situation solely on the information provided by CSL Behring.
The Foundation encourages patients to contact their pharmacy regarding their prescription of Zemaira and discuss their treatment with their physicians. The Foundation also assumes the responsibility of keeping the Alpha-1 community informed about further developments of this situation.
Click For Search Options
Enter keywords in text box and click Search button for results.
3300 Ponce de Leon Blvd. Coral Gables, FL 33134
Phone: (877) 228-7321 Email: firstname.lastname@example.org